Hussein Yassine is an Endocrinology/Metabolic physician affiliated with University of Southern California. OpenAlex indexes 193 publications with 2,930 citations (h-index 32); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- DHA Brain Delivery Trial
Sponsor: University of Southern California
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
100%Statin100%Rosuvastatin Calcium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
13 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- Drug Development for Alzheimer's neuroinflammation
University of Southern California
FY2026$1,672,123U01AG094622 - Brain cPLA2 as a mechanism for neuroinflammation in AD/ADRD with and without APOE4
University of Southern California
FY2026$787,497R01AG076124
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cellular senescence induced by cholesterol accumulation is mediated by lysosomal ABCA1 in APOE4 and AD
Molecular Neurodegeneration
2025 - Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference
Alzheimer s & Dementia
2024 - Effects of APOE4 on omega-3 brain metabolism across the lifespan
Trends in Endocrinology and Metabolism
2024 - Development of Calcium-Dependent Phospholipase A2 Inhibitors to Target Cellular Senescence and Oxidative Stress in Neurodegenerative Diseases
Antioxidants and Redox Signaling
2024
Similar KOLs
Other experts from the same institution or the same specialty.
David Liebeskind, MD
University of Southern California
Lon Schneider, MD
University of Southern California
Amytis Towfighi, MD
University of Southern California
Norah Terrault, MD
University of Southern California
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”